This Article Full Text Full Text (PDF) All Versions of this Article: 91/11/4438    most recent Author Manuscript (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hadigan, C. Articles by Grinspoon, S. Search for Related Content PubMed PubMed Citation Articles by Hadigan, C. Articles by Grinspoon, S. Related Collections Lipid Metabolism

Improved Triglycerides and Insulin Sensitivity with 3 Months of Acipimox in Human Immunodeficiency Virus-infected Patients with Hypertriglyceridemia

Program in Nutritional Metabolism (C.H., J.L., R.A., S.G.) and Division of Musculoskeletal Radiology (M.T.), Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114

Address all correspondence and requests for reprints to: Colleen Hadigan, M.D., M.P.H., National Institutes of Health, National Institute of Allergy and Infectious Diseases, 10 Center Drive, Building 10, Room 11C103, Bethesda, Maryland 20892. E-mail: hadiganc{at}niaid.nih.gov.

Context: Metabolic abnormalities such as hypertriglyceridemia remain a challenge for optimizing long-term health in HIV-infected patients.

Objective: Elevation of free fatty acids (FFAs) may contribute to hyperlipidemia and insulin resistance in HIV. We evaluated the efficacy and safety of chronic inhibition of lipolysis in HIV-infected men and women with hypertrigyceridemia. We hypothesized that acipimox would lead to significant reductions in triglycerides and improved insulin sensitivity, compared with placebo.

Design: A 3-month, randomized, double-blind, controlled trial of acipimox (250 mg thrice daily) vs. placebo was conducted in 23 HIV-infected men and women with hypertriglyceridemia (>150 mg/dl), abnormal fat distribution, and no current lipid-lowering therapy. The primary outcome variable was triglyceride concentration, and insulin sensitivity measured by hyperinsulinemic euglycemic clamp was a secondary outcome.

Setting: The study was conducted at an academic medical center.

Results: Acipimox resulted in significant reductions in FFAs [mean change –0.38 (0.06) vs. 0.08 (0.06) mEq/liter with placebo, –68 vs. +17% change from mean baseline, P < 0.0001], decreased rates of lipolysis (P < 0.0001), and a median triglyceride decrease from 238 mg/dl at baseline to 190 mg/dl, compared with an increase from 290 to 348 mg/dl in the placebo group (P = 0.01). Acipimox improved insulin sensitivity [acipimox +2.31 (0.74) vs. placebo –0.21 (0.90) mg glucose per kilogram lean body mass per minute, or +31 vs. –2% change from mean baseline values, P = 0.04]. Improvements in insulin sensitivity were significantly correlated with reductions in FFAs (r = –0.62, P = 0.003) and lipolysis (r = –0.59, P = 0.005).

Conclusions: Acipimox resulted in significant sustained reductions in lipolysis, improved glucose homeostasis, and significant but modest reductions in triglycerides in HIV-infected individuals with abnormal fat distribution and hypertriglyceridemia. Improvement in overall metabolic profile with acipimox suggests a potential clinical utility for this agent that requires further investigation.

This article has been cited by other articles:

				K. Samaras Metabolic consequences and therapeutic options in highly active antiretroviral therapy in human immunodeficiency virus-1 infection J. Antimicrob. Chemother., February 1, 2008; 61(2): 238 - 245. [Abstract] [Full Text] [PDF]

				B. Lindegaard, C. Frosig, A. M. W. Petersen, P. Plomgaard, S. Ditlevsen, B. Mittendorfer, G. Van Hall, J. F.P. Wojtaszewski, and B. K. Pedersen Inhibition of Lipolysis Stimulates Peripheral Glucose Uptake but Has No Effect on Endogenous Glucose Production in HIV Lipodystrophy Diabetes, August 1, 2007; 56(8): 2070 - 2077. [Abstract] [Full Text] [PDF]